Dr. Vineet Govinda Gupta

Dr. Vineet Govinda Gupta is an Additional Director and Unit Head of Medical Oncology at Fortis Hospital, Shalimar Bagh, New Delhi, bringing over 12 years of clinical expertise in comprehensive cancer care. A graduate of the All India Institute of Medical Sciences (AIIMS), New Delhi, he holds an MBBS, MD in Medicine, and a DM in Medical Oncology, achieving Gold Medal distinction in his oncology specialization. He is also a European Certified Medical Oncologist (ECMO), reflecting his commitment to international standards of evidence-based cancer treatment.

Dr. Gupta's clinical depth spans chemotherapy for solid tumors, adjuvant and neoadjuvant regimens, palliative chemotherapy, immune checkpoint inhibitor therapy, immunotherapy for advanced malignancies, biomarker-based targeted therapy, and molecular-targeted approaches. He has particular expertise in hormone therapy for breast, prostate, and gynaecologic cancers. His research contributions include publications in top-tier international journals such as the Journal of Clinical Oncology, The Lancet Oncology, and the New England Journal of Medicine. Notably, he led one of India's first retrospective studies on immunotherapy drugs in 2018, establishing himself as a thought leader in cancer immunology.

Dr. Gupta is known for treating international patients from the Gulf States, Africa, and across South Asia with the same rigorous, evidence-based approach and personal compassion he brings to all patients. He views each case through the lens of personalized medicine, integrating molecular insights and genomic profiling to tailor treatment plans. His philosophy centres on treating every patient as he would his own family, ensuring comfort, clarity, and the best possible outcomes throughout their cancer journey.

Fortis Hospital, Shalimar Bagh, is a leading quaternary-care institution in Delhi equipped with advanced oncology facilities, dedicated ICU support, and a well-established international patient services desk. The hospital's accreditations and state-of-the-art infrastructure make it an ideal destination for international cancer patients seeking world-standard treatment. New Delhi's strategic location, combined with Fortis's reputation for clinical excellence and affordability, positions it as a preferred hub for medical tourists across the Middle East, Africa, and Central Asia seeking specialist oncology care.